Rho

Pharmabiz.com | July 10, 2017

Data from 77 countries show that antibiotic resistance is making gonorrhoea – a common sexually-transmitted infection – much harder, and sometimes impossible, to treat. "The bacteria that cause gonorrhoea are particularly smart. Every time we use a new class of antibiotics to treat the infection, the bacteria evolve to resist them," said Dr Teodora Wi, Medical Officer, Human Reproduction, at WHO. WHO reports widespread resistance to older and cheaper antibiotics. Some countries – particularly hi...

pharma times | July 12, 2017

Researchers in New Zealand have found that teenagers given a meningitis B vaccine were significantly less likely to contract gonorrhoea, marking the first time a vaccine has shown any protection against the sexually transmitted infection (STI). The retrospective, case-control study, published in The Lancet, found a 31 percent reduction in the incidence of gonorrhoea amongst those vaccinated with the meningitis B jab. "At the moment, the mechanism behind this immune response is unknown, but our f...

News Medical Life Sciences | September 11, 2017

Statins used for the treatment of high cholesterol may have other beneficial effects, but there has been reluctance to prescribe them to patients with liver disease because of concerns that they may cause abnormal liver enzyme levels in the blood. In a new Alimentary Pharmacology & Therapeutics analysis of data from the Danish National Patient Registry, patients with cirrhosis of the liver due to alcohol had a 43% lower risk of dying prematurely than patients not on statins....

Pharmaphorum Media Limited | August 16, 2018

Pfizer is to pay German company BioNTech up to $425m for a multi-year collaboration in the development of more effective influenza vaccines, joining other pharma giants in a promising mRNA-based race. Under the terms of the agreement, BioNTech received a $120m upfront payment consisting of a mix of cash, equity, and research support. Pfizer has also committed to an additional $305m in line with potential regulatory and commercial milestone payments depending on the future development achievement...